Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418).
- Author:
Yeon Joo KIM
1
;
Won PARK
;
Boram HA
;
Boram PARK
;
Jungnam JOO
;
Tae Hyun KIM
;
In Hae PARK
;
Keun Seok LEE
;
Eun Sook LEE
;
Kyung Hwan SHIN
;
Haeyoung KIM
;
Jeong Il YU
;
Doo Ho CHOI
;
Seung Jae HUH
;
Chan Woo WEE
;
Kyubo KIM
;
Kyung Ran PARK
;
Yong Bae KIM
;
Sung Ja AHN
;
Jong Hoon LEE
;
Jin Hee KIM
;
Mison CHUN
;
Hyung Sik LEE
;
Jung Soo KIM
;
Jihye CHA
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Breast neoplasms; Radiotherapy; Taxane; Recurrence; Disease-free survival; Survival
- MeSH: Breast Neoplasms*; Breast*; Disease-Free Survival; Drug Therapy*; Follow-Up Studies; Humans; Mastectomy, Modified Radical; Radiotherapy*; Recurrence; Retrospective Studies*
- From:Cancer Research and Treatment 2017;49(4):927-936
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. MATERIALS AND METHODS: We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. RESULTS: We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). CONCLUSION: PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.
